Evidence map›Paper›PMID 26247470›Full record

ArticlePloS one2015

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.

Benoit Visseaux, Charlotte Charpentier, Gilles Collin, Mélanie Bertine, Gilles Peytavin, Florence Damond, Sophie Matheron, Eric Lefebvre, Françoise Brun-Vézinet, Diane Descamps and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Benoit VisseauxINSERM, IAME, UMR 1137, Paris, France; Univ Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Bichat, Laboratoire de Virologie, Paris, France.
Charlotte CharpentierINSERM, IAME, UMR 1137, Paris, France; Univ Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Bichat, Laboratoire de Virologie, Paris, France.
Gilles CollinINSERM, IAME, UMR 1137, Paris, France; Univ Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Bichat, Laboratoire de Virologie, Paris, France.
Mélanie BertineINSERM, IAME, UMR 1137, Paris, France; Univ Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Bichat, Laboratoire de Virologie, Paris, France.
Gilles PeytavinINSERM, IAME, UMR 1137, Paris, France; Univ Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Bichat, Pharmacologie des antirétroviraux, Paris, France.
Florence DamondINSERM, IAME, UMR 1137, Paris, France; Univ Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Bichat, Laboratoire de Virologie, Paris, France.
Sophie MatheronINSERM, IAME, UMR 1137, Paris, France; Univ Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Bichat, Service des Maladies Infectieuses et Tropicales, Paris, France.
Eric LefebvreTobira Therapeutics, Inc., South San Francisco, CA, United States of America.
Françoise Brun-VézinetINSERM, IAME, UMR 1137, Paris, France; Univ Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Bichat, Laboratoire de Virologie, Paris, France.
Diane DescampsINSERM, IAME, UMR 1137, Paris, France; Univ Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Bichat, Laboratoire de Virologie, Paris, France.
ANRS CO5 HIV-2 Cohort
Délégation Paris 7 · FRHôpital Bichat-Claude-Bernard · FRUniversité Paris Cité · FRNkarta Therapeutics (United States) · USSorbonne Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMaraviroc activity against HIV-2, a virus naturally resistant to different HIV-1 antiretroviral drugs, has been recently demonstrated. The aim of this study was to assess HIV-2 susceptibility to cenicriviroc, a novel, once-daily, dual CCR5 and CCR2 antagonist that has completed Phase 2b development in HIV-1 infection.

methodsCenicriviroc phenotypic activity has been tested using a PBMC phenotypic susceptibility assay against four R5-, one X4- and one dual-tropic HIV-2 clinical primary isolates. All isolates were obtained by co-cultivation of PHA-activated PBMC from distinct HIV-2-infected CCR5-antagonist-naïve patients included in the French HIV-2 cohort and were previously tested for maraviroc susceptibility using the same protocol. HIV-2 tropism was determined by phenotypic assay using Ghost(3) cell lines.

resultsRegarding the 4 R5 HIV-2 clinical isolates tested, effective concentration 50% EC50 for cenicriviroc were 0.03, 0.33, 0.45 and 0.98 nM, similar to those observed with maraviroc: 1.13, 0.58, 0.48 and 0.68 nM, respectively. Maximum percentages of inhibition (MPI) of cenicriviroc were 94, 94, 93 and 98%, similar to those observed with maraviroc (93, 90, 82, 100%, respectively). The dual- and X4-tropic HIV-2 strains were resistant to cenicriviroc with EC50 >1000 nM and MPI at 33% and 4%, respectively.

conclusionsIn this first study assessing HIV-2 susceptibility to cenicriviroc, we observed an in vitro activity against HIV-2 R5-tropic strains similar to that observed with maraviroc. Thus, cenicriviroc may offer a once-daily treatment opportunity in the limited therapeutic arsenal for HIV-2. Clinical studies are warranted.

Indexed as

Anti-HIV AgentsCCR5 Receptor AntagonistsCells, CulturedCoculture TechniquesCyclohexanesHIV-2HIV InfectionsHumansImidazolesLeukocytes, MononuclearMaravirocPhenotypePhytohemagglutininsReceptors, CCR2Receptors, CCR5SulfoxidesAnti-HIV AgentsCCR5 Receptor AntagonistscenicrivirocCyclohexanesImidazolesMaravirocPhytohemagglutininsReceptors, CCR2Receptors, CCR5SulfoxidesTriazoles

Identifiers

PMID26247470
PMCPMC4527700
OpenAlexW1923146424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.